HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Aprea Therapeutics (NASDAQ:APRE) and maintains a $20 price target.
May 14, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Aprea Therapeutics with a $20 price target, indicating a positive outlook on the company's stock.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong belief in the company's future performance. This endorsement is likely to instill confidence in investors, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100